source
- London biotech Oyster raises $60 million to develop tau-targeting protein degradersOyster Therapeutics, a London-based biotech, announced it has secured $60 million in an extension of its Series A financing round. The funding will support its lead program that uses a modified pr…
- Acting FDA commissioner reports strong public interest in new expedited IND pilotActing FDA Commissioner Kyle Diamantas told attendees at the Friends of Cancer Research annual meeting that the agency’s newly launched Expedited IND pilot has attracted considerable public attenti…